We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock

Delisted

FNCH was delisted on the 24th of May, 2024.

46 hedge funds and large institutions have $28M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

13% less funds holding

Funds holding: 5346 (-7)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

47% less capital invested

Capital invested by funds: $53.1M → $28M (-$25.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $3K

Holders
46
Holders Change
-7
Holders Change %
-13.21%
% of All Funds
0.77%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
11
Reduced
12
Closed
14
Calls
Puts
$3K
Net Calls
-$3K
Net Calls Change
-$3K

FNCH Hedge Fund Activity: Q2 2022 in Review

46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2022, worth a combined $28M — down 47% from $53.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of FNCH and 8 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 11 added.

The largest buyer was Oasis Management Company, opening a new position worth an estimated $641K. The largest seller was Light Street Capital Management, exiting entirely with an estimated $3.36M sold.

  • 46 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2022, down from 53 in Q1 2022.
  • Funds reported $28M of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2022, down 47% quarter-over-quarter.
  • 8 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2022 and 14 closed out, a net change of -6 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q2 2022 was Oasis Management Company, an estimated $641K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2022 was Light Street Capital Management, an estimated $3.36M sold.

Based on aggregated 13F filings for Q2 2022.